We claim:

1. A compound of the formula



where R^1 and R^2 are each independently hydrogen, C_1-C_3 alkoxycarbonyloxymethyl, C_1-C_5 alkylcarbonyloxymethyl, or C_{3-6} cycloalkylcarbonyloxymethyl;

R^3 is independently at each occurance methyl, fluoro, or chloro;

R^4 is hydroxyl, amino, methylcarbonylamino, or 1,2,4-triazolylthio; and

n is 1 or 2;

or a pharmaceutically acceptable salt thereof.

2. The compound according to Claim 1 where R^1 and R^2 are each hydrogen, or a pharmaceutically acceptable salt thereof.

3. The compound according to Claim 1 where R^1 and R^2 are both other than hydrogen, or a pharmaceutically acceptable salt thereof.

4. The compound according to Claim 1 where R^1 and R^2 are the same and are other than hydrogen, or a pharmaceutically acceptable salt thereof.

5. The compound according to Claim 4 where R^1 and R^2 are each isopropyloxycarbonyloxymethyl.

6. The compound according to any one of Claims 1 through 5 where n is 2 and the R^3 groups are at the phenyl 3- and 4-positions.

7. The compound according to any one of Claims 1 through 6 where R^3 is independently at each occurance chloro or fluoro.

8. The compound according to Claim 1 which is (1S,2R,3S,4S,5R,6R)-2-amino-3-{[(3,4-difluorophenyl)sulfanyl]methyl}-4-hydroxybicyclo[3.1.0] hexane-2,6-dicarboxylic acid, or a pharmaceutically acceptable salt thereof.

9. The compound according to Claim 1 which is bis({[(1-methylethoxy)carbonyl]oxy}methyl) (1S,2R,3S,4S,5R,6R)-2-amino-3-{[(3,4-difluorophenyl)sulfanyl]methyl}-4-hydroxybicyclo[3.1.0]hexane-2,6-dicarboxylate or a pharmaceutically acceptable salt thereof.

10. The compound according to Claim 1 which is (1S,2R,3S,4S,5R,6R)-2-amino-3-{[(3-chloro-4-fluorophenyl)sulfanyl]methyl}-4-hydroxybicyclo[3.1.0] hexane-2,6-dicarboxylic acid, or a pharmaceutically acceptable salt thereof.

11. The compound according to Claim 1 which is bis({[(1-methylethoxy)carbonyl]oxy}methyl) (1S,2R,3S,4S,5R,6R)-2-amino-3-{[(3-chloro-4-fluorophenyl)sulfanyl]methyl}-4-hydroxybicyclo[3.1.0]hexane-2,6-dicarboxylate, or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising a compound according to any one of Claims 1 to 11, or a pharmaceutically acceptable salt thereof, in combination with at least one pharmaceutically acceptable carrier, excipient or diluent.

13. Use of a compound according to any one of Claims 1 to 11, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of depressive disorders.

14. Use of a compound according to any one of Claims 1 to 11, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of disorders of excessive sleepiness.

15. Use of a compound according to any one of Claims 1 to 11, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of depressive disorders, wherein said medicament is to be administered in simultaneous, separate or sequential combination with a serotonin reuptake inhibitor.

16. The use according to Claim 15 where the serotonin reuptake inhibitor is fluoxetine or citalopram.

17. The use according to Claim 15 or 16 in a human.

18. A pharmaceutical composition comprising a compound according to any one of Claims 1 to 11, or a pharmaceutically acceptable salt thereof and a serotonin reuptake inhibitor in combination with at least one pharmaceutically acceptable carrier, excipient or diluent.

19. The pharmaceutical composition of Claim 18 wherein the serotonin reuptake inhibitor is fluoxetine or citalopram.

We claim:

1. A compound of the formula



where R^1 and R^2 are each independently hydrogen, C_1-C_3 alkoxycarbonyloxymethyl, C_1-C_5 alkylcarbonyloxymethyl, or C_{3-6} cycloalkylcarbonyloxymethyl;

R^3 is independently at each occurance methyl, fluoro, or chloro;

R^4 is hydroxyl, amino, methylcarbonylamino, or 1,2,4-triazolylthio; and

n is 1 or 2;

or a pharmaceutically acceptable salt thereof.

2. The compound according to Claim 1 where R^1 and R^2 are each hydrogen, or a pharmaceutically acceptable salt thereof.

3. The compound according to Claim 1 where R^1 and R^2 are both other than hydrogen, or a pharmaceutically acceptable salt thereof.

4. The compound according to Claim 1 where R^1 and R^2 are the same and are other than hydrogen, or a pharmaceutically acceptable salt thereof.

5. The compound according to Claim 4 where R^1 and R^2 are each isopropyloxycarbonyloxymethyl.

6. The compound according to any one of Claims 1 through 5 where n is 2 and the R^3 groups are at the phenyl 3- and 4-positions.

7. The compound according to any one of Claims 1 through 6 where R^3 is independently at each occurance chloro or fluoro.

8. The compound according to Claim 1 which is (1S,2R,3S,4S,5R,6R)-2-amino-3-{[(3,4-difluorophenyl)sulfanyl]methyl}-4-hydroxybicyclo[3.1.0] hexane-2,6-dicarboxylic acid, or a pharmaceutically acceptable salt thereof.

9. The compound according to Claim 1 which is bis({[(1-methylethoxy)carbonyl]oxy} methyl) (1S,2R,3S,4S,5R,6R)-2-amino-3-{[(3,4-difluorophenyl)sulfanyl]methyl}-4-hydroxybicyclo[3.1.0]hexane-2,6-dicarboxylate or a pharmaceutically acceptable salt thereof.

10. The compound according to Claim 1 which is (1S,2R,3S,4S,5R,6R)-2-amino-3-{[(3-chloro-4-fluorophenyl)sulfanyl]methyl}-4-hydroxybicyclo[3.1.0] hexane-2,6-dicarboxylic acid, or a pharmaceutically acceptable salt thereof.

11. The compound according to Claim 1 which is bis({[(1-methylethoxy)carbonyl]oxy} methyl) (1S,2R,3S,4S,5R,6R)-2-amino-3-{[(3-chloro-4-fluorophenyl)sulfanyl]methyl}-4-hydroxybicyclo[3.1.0]hexane-2,6-dicarboxylate, or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising a compound according to any one of Claims 1 to 11, or a pharmaceutically acceptable salt thereof, in combination with at least one pharmaceutically acceptable carrier, excipient or diluent.

13. A compound according to any one of Claims 1 to 11, or a pharmaceutically acceptable salt thereof, for use in therapy.

14. A compound according to any one of Claims 1 to 11, or a pharmaceutically acceptable salt thereof, for use in the treatment of depressive disorders.

15. A compound according to any one of Claims 1 to 11, or a pharmaceutically acceptable salt thereof, for use in the treatment of disorders of excessive sleepiness.

16. The compound for use according to Claim 14 or 15 in a human.

17. A compound according to any one of Claims 1 to 11, or a pharmaceutically acceptable salt thereof, for use in simultaneous, separate or sequential combination with a serotonin reuptake inhibitor in the treatment of depressive disorders.

18. The compound for use according to Claim 17 where the serotonin reuptake inhibitor is fluoxetine or citalopram.

19. The compound for use according to Claim 17 or 18 in a human.

20. A method for treating depressive disorders in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

21. The method of Claim 20 where the mammal is a human.

22. A method for treating disorders of excessive sleepiness in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

23. The method of Claim 22 where the mammal is a human.

24. A method for treating depressive disorders in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, in simultaneous, separate or sequential combination with a serotonin reuptake inhibitor.

25. The method of Claim 24 wherein the serotonin reuptake inhibitor is fluoxetine or citalopram.

26. The method of Claim 24 wherein the mammal is a human.

27. The method of Claim 25 wherein the mammal is a human.

28. A pharmaceutical composition comprising a compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, in combination with at least one pharmaceutically acceptable carrier, excipient or diluent, and optionally other therapeutic ingredients.

29. A pharmaceutical composition comprising a compound according to any one of Claims 1 to 11, or a pharmaceutically acceptable salt thereof and a serotonin reuptake inhibitor in combination with at least one pharmaceutically acceptable carrier, excipient or diluent.

30. The pharmaceutical composition of Claim 29 wherein the serotonin reuptake inhibitor is fluoxetine or citalopram.